Alex Fonollosa1,2,3, José Hernández-Rodríguez4, Carlos Cuadros1, Lena Giralt1, Cristina Sacristán1, Joseba Artaraz1, Laura Pelegrín5, Álvaro Olate-Pérez5, Rosa Romero6, Salvador Pastor-Idoate3,7,8, Eva María Sobas Bsc7, Sonia Fernández-Fidalgo9, Maximino J Abraldes3,9,10, Andrea Oleñik11, Alfredo Insausti-García12, Pedro Torres13, Carmela Porcar14, Daniela Rego Lorca15, Alfredo Adan5. 1. Department of Ophthalmology, BioCruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain. 2. Instituto Oftalmológico Bilbao, Bilbao, Spain. 3. Cooperative Health Network for Research in Ophthalmology (Oftared), National Institute of Health Carlos III, ISCIII, Madrid, Spain. 4. Vasculitis Research Unit and Clinical Unit of Autoinflammatory Diseases, Department of Autoimmune Diseases, Hospital Clínic de Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. 5. Department of Ophthalmology, Institut Clínic d'Oftalmologia (ICOF), Hospital Clinic de Barcelona, University of Barcelona, Institut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 6. CIENI (Centro de Investigación en enfermedades infecciosas)-INER (Instituto Nacional de Enfermedades Respiratorias), Méjico DF, Méjico. 7. Clinical University Hospital of Valladolid, Valladolid, Spain. 8. Institute of Applied Ophthalmobiology (IOBA), University of Valladolid, Valladolid, Spain. 9. Servicio de Oftalmología, Complexo Hospitalario Universitario de Santiago de Compostela. 10. Departamento de Cirugía y Especialidades Médico-Quirúrgicas, Universidad de Santiago de Compostela, Santiago de Compostela, A Coruña, España. 11. Hospital Quiron Toledo, Toledo, Spain. 12. Department of Ophthalmology, University Hospital 12 de Octubre, Madrid, Spain. 13. Hospital Oftalmológico Juan Domingo Perón, Buenos Aires, Argentina. 14. Department of Ophthalmology, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain; and. 15. Servicio de Oftalmología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
Abstract
PURPOSE: To describe clinical and ophthalmologic features and outcomes of patients with coronavirus disease-19 with retinal vascular occlusions. METHODS: Retrospective multicenter case series and PubMed review of cases reported from March 2020 to September 2021. Outcome measures are as follows: type of occlusion, treatments, best-corrected visual acuity, and central macular thickness on optical coherence tomography. RESULTS: Thirty-nine patients were identified. Fifteen patients with a median age of 39 (30-67) years were included in the multicenter study. Vascular occlusions included central retinal vein occlusion (12 eyes), branch retinal vein occlusion (4 eyes), and central retinal artery occlusion (2 eyes). Three cases were bilateral. Baseline best-corrected visual acuity was 20/45 (no light perception-20/20). Baseline central macular thickness was 348.64 (±83) μm. Nine eyes received anti-vascular endothelial growth factor agents, dexamethasone intravitreal implant, or both. Final best-corrected visual acuity was 20/25 (no light perception-20/20), and central macular thickness was 273.7 ± 68 μm (follow-up of 19.6 ± 6 weeks). Among the 24 cases from the literature review, retinal vein occlusion was the predominant lesion. Clinical characteristics and outcomes were similar to those found in our series. CONCLUSION: Coronavirus disease-19-associated retinal vascular occlusions tend to occur in individuals younger than 60 years. Retinal vein occlusion is the most frequent occlusive event, and outcomes are favorable in most cases.
PURPOSE: To describe clinical and ophthalmologic features and outcomes of patients with coronavirus disease-19 with retinal vascular occlusions. METHODS: Retrospective multicenter case series and PubMed review of cases reported from March 2020 to September 2021. Outcome measures are as follows: type of occlusion, treatments, best-corrected visual acuity, and central macular thickness on optical coherence tomography. RESULTS: Thirty-nine patients were identified. Fifteen patients with a median age of 39 (30-67) years were included in the multicenter study. Vascular occlusions included central retinal vein occlusion (12 eyes), branch retinal vein occlusion (4 eyes), and central retinal artery occlusion (2 eyes). Three cases were bilateral. Baseline best-corrected visual acuity was 20/45 (no light perception-20/20). Baseline central macular thickness was 348.64 (±83) μm. Nine eyes received anti-vascular endothelial growth factor agents, dexamethasone intravitreal implant, or both. Final best-corrected visual acuity was 20/25 (no light perception-20/20), and central macular thickness was 273.7 ± 68 μm (follow-up of 19.6 ± 6 weeks). Among the 24 cases from the literature review, retinal vein occlusion was the predominant lesion. Clinical characteristics and outcomes were similar to those found in our series. CONCLUSION: Coronavirus disease-19-associated retinal vascular occlusions tend to occur in individuals younger than 60 years. Retinal vein occlusion is the most frequent occlusive event, and outcomes are favorable in most cases.
Authors: Vittorio Capuano; Paolo Forte; Riccardo Sacconi; Alexandra Miere; Carl-Joe Mehanna; Caterina Barone; Francesco Bandello; Eric H Souied; Giuseppe Querques Journal: Eur J Ophthalmol Date: 2022-03-31 Impact factor: 2.597